We are interested in using C. elegans as a model system to identify novel small molecules useful for biological analyses. In a previous screen of 11,000 compounds with little or no annotation for bioactivity, we observed 173 (1.6%) molecules that induce obvious phenotypes (Kwok et al., 2006). One contributing factor that may account for this low hit rate is that only 6.9% of small molecules accumulate significantly in worm tissue (see Burns et al abstract). To test if pre-screening molecules for bioavailability increases the hit rate, we assembled 3700 molecules that are bioactive (and therefore bioavailable) in budding yeast. From these, we identified 1058 compounds that induce a strong worm phenotype, which is a 17.8-fold increase in the hit rate compared to that observed with the 11,000 naive molecules (above). Excitingly, one of these bioactive compounds, which we call dafadine-A, induces protruding vulva, distal tip cell migration defects, and constitutive dauer formation (Daf-c). We screened 159 structural analogs of dafadine-A and found three molecules that have dafadine-like properties. To our knowledge, dafadine molecules are not currently annotated for bioactivity. Because of the phenotypic profile of dafadine-treated worms, we hypothesize that dafadine may antagonize DAF-9, a cytochrome
p450 that helps synthesize a cholesterol-derived ligand for the nuclear hormone receptor DAF-12. Alternatively, dafadine might antagonize ligand interaction with DAF-12, similar to the
daf-12 class 6 alleles that likely disrupt ligand binding and result in a Daf-c phenotype (Antebi et al., 2000). By contrast,
daf-12 alleles that are null or disrupt DNA-binding are dauer-defective (Daf-d). To test our hypothesis, we first asked if a Daf-d null mutant upstream of
daf-9 could suppress the effects of dafadine. Animals null for
daf-16 remain sensitive to dafadine, consistent with our hypothesis. Next, we tested if
daf-12 null alleles suppress the defects induced by dafadine; both
m20 and
rh61rh411 nulls are Daf-d when raised on dafadine. Together, these results suggest that dafadine antagonizes either DAF-9 or ligand interaction with DAF-12. Genetic analysis of dafadine in both yeast and worms is ongoing.